1. Introduction
The retina comprises diverse differentiated neurons that have specific functions. Photoreceptor cells, the first-order neurons in the retina, have photopigments (rhodopsin and opsin) that absorb photons. Signals produced by the photoreceptor cells are transmitted to second-order neurons. Finally, visual signals are transmitted to the brain from the third-order neurons, the retinal ganglion cells (RGCs). Major diseases that cause blindness in advanced countries include glaucoma, diabetic retinopathy, retinitis pigmentosa (RP), and age-related retinopathy. Loss of vision due to these diseases is irreversible. However, with regard to glaucoma, eye drops that have the effect of reducing intraocular pressure have been developed. In diabetic retinopathy, effective surgical treatments such as vitrectomy and photocoagulation have been established. Blindness due to glaucoma and diabetic retinopathy can be prevented by administering these treatments in the early phase. On the other hand, in diseases caused by gene mutations, such as RP, effective treatments for delaying photoreceptor degeneration have not yet been established. Degeneration of photoreceptor cells results in loss of vision, even if other retinal neurons are intact [1-3].
RP is a disease that causes blindness due to photoreceptor degeneration. Symptoms include night blindness and loss of peripheral and central vision. Approximately 1 in 4,000 people are affected by this disease [4]. In 1990, Dryja et al. [5] first identified a point mutation in the rhodopsin gene from RP patients. A number of gene mutations responsible for RP has subsequently been identified. Most of these genes are associated with the phototransduction pathway in the retina. In some cases, the mutated gene exists not only in photoreceptor cells but also in retinal pigment epithelial cells. To date, 53 causative genes and 7 loci of RP have been identified (http://www.sph.uth.tmc.edu/Retnet/). Leber’s congenital amaurosis (LCA) is another retinal degenerative disease predicted to affect approximately 1/81000 individuals [6]. Most LCA patients have severe visual defects in childhood. Histological analysis of the retinas of LCA patients shows marked retinal atrophy in the outer retinal layer, vascular thickening and sclerosis, and atrophy of the retinal pigment epithelium (RPE) [7]. Leber classified the disease as a type of RP on the basis of these characteristics. Later, Franceschetti and Dieterle differentiated it from retinal dystrophy based on the features of electroretinograms (ERGs) in these patients. Many gene mutations involved in LCA have been identified and the disease has been classified into 15 subtypes based on the affected gene [8-13]. Among these, LCA2, accounting for 10% of LCA cases [14], is due to a mutation in the RPE65 gene, which encodes all-
A retinal prosthesis, comprising electrodes, an image processor, and a camera, is the only method to restore vision that has been studied [32-36]. Recently, a new strategy involving gene therapy for restoring vision has been developed using bacteriorhodopsin family genes [37,38]. The channelrhodopsin-2 (ChR2) gene derived from the green alga
2. Materials and methods
All the experiments performed for this report were approved by the Tohoku University Animal Care Committee, which is accredited by the Ministry of Education, Culture, Sports, Science, and Technology of Japan. Every effort was made to minimize the number and suffering of animals used in the following experiments.
We used 2 types of photoreceptor degeneration models: a genetically blind rat model and a light-induced photoreceptor degeneration model. The experimental design for each of these models is shown in Fig. 1.
Royal College of Surgeons (RCS; rdy/rdy) rats [43,44] were used as model animals for photoreceptor degeneration in our experiments. The RCS rat, an animal model of recessively inherited retinal degeneration, is widely used in the study of photoreceptor degeneration. The gene responsible is the receptor tyrosine kinase gene Mertk [45], and mutations in MERTK, the human ortholog of the RCS rat retinal dystrophy gene, cause RP [46]. Photoreceptor degeneration is almost complete by 3 months after birth. We intravitreously injected the AAV-ChR2V vector into 6-month- or 10-month-old RCS rats. The rats were obtained from CLEA Japan, Inc. (Tokyo, Japan).
We established transgenic (TG) rats harboring the ChR2 gene regulated by the Thy-1.2 promoter to investigate contrast sensitivity at each spatial frequency [47]. The rat Thy-1.2 antigen has been found to be abundant in the brain and thymus [48,49]. In the retina, the Thy-1.2 antigen is recognized as a marker specific to RGCs [50,51]. It is necessary to induce the degeneration of native photoreceptor cells in order to investigate the visual function conferred by ChR2-expressing RGCs, because the Thy-I TG rat has native photoreceptor cells. For this purpose, Thy-I TG rats were subjected to light-induced photoreceptor degeneration. Briefly, Thy-I TG rats were kept in cyclic light (12 hours ON/OFF: 5–10 lux/dark) for at least 2 weeks prior to light exposure. The rats were then exposed to a 3000-lux intensity of fluorescent light for 7 days [28]. We used a light exposure box (NK Systems, Tokyo, Japan) to control the timing and light intensity for the induction of photoreceptor degeneration. After induction, we recorded ERGs to confirm photoreceptor degeneration.
Preparation of the adeno-associated virus vector
The adeno-associated virus (AAV) vector with the ChR2 gene was constructed as described previously [38]. Following this, the AAV Helper-Free System (Stratagene, La Jolla, CA) was used to produce infectious AAV-Venus (control) and AAV-ChR2V virions, which were purified by a single-step column purification method as previously described [52].
Recording of ERGs and visual electrophysiology (VEP)
ERGs and VEP readings were recorded using a Neuropack (MEB-9102; Nihon Kohden, Tokyo, Japan) according to methods previously described [38,53]. Briefly, rats were dark-adapted overnight, and the pupils were dilated with 1% atropine and 2.5% phenylephrine hydrochloride. Small contact lenses with gold wire loops were placed on both corneas, and a silver wire reference electrode was inserted subcutaneously between the eyes. Eyes were stimulated with flash light stimuli of 10-ms duration using a blue LED. Full-field scotopic ERGs were recorded, band-pass filtered at 0.3–500 Hz, and averaged for 5 responses at each light intensity. For VEP recordings, recording electrodes (silver-silver chloride) were placed epidurally on each side, 7 mm behind the bregma and 3 mm lateral of the midline, and a reference electrode was placed epidurally on the midline 12 mm behind the bregma, at least 7 days before the experiments [54,55]. Under ketamine-xylazine anesthesia, the pupils were dilated with 1% atropine and 2.5% phenylephrine hydrochloride. The ground electrode clip was placed on the tail. Photic stimuli of 20-ms duration were generated under various intensities by pulse activation of a blue LED. The high- and low-pass filters were set to 50 kHz and 0.05 kHz, respectively. One hundred consecutive response waveforms were averaged for each VEP measurement.
Determination of transduction efficiency
At the end of the experiment, RCS and Thy-TG rats were sacrificed, and their eyes were resected and fixed in 4% paraformaldehyde and 0.1 M phosphate buffer, pH 7.4 [56]. The eye of each rat was flat-mounted on a slide and covered with Vectashield medium (Vector Laboratories, Burlingame, CA) to prevent the degradation of fluorescence. Then, the number of positive cells was counted.
3. Behavioral assessment
The spatial vision of each animal was quantified by its optomotor response. We used a virtual optomotor system to evaluate the contrast sensitivities of each spatial frequency. The original virtual optomotor system described by Prusky et al. [57] was modified for rats [47]. When a drum is rotated around an animal with printed visual stimuli on the inside wall, the animal tracks the stimulus by turning its head. A light-dark grating pattern was displayed on computer monitors (ProLite E1902WS; Iiyama, Tokyo, Japan) arranged in a square around a platform. The software controlled the speed of virtual optomotor rotation, which was set at 12 degrees per second (2 rpm) in all experiments. The spatial frequency and the contrast of the grating pattern were varied but the average brightness was kept constant.
The animal was allowed to move freely on the platform in the virtual optomotor system. The grating session was started at a low spatial frequency (0.06 cycles/degree) with maximal contrast. An experimenter assessed whether the animals tracked the rotation, by monitoring the head movement and the presented rotating stimulus simultaneously on another display connected to the video camera. If head movement simultaneous with the rotation was evident, the experimenter judged that the animal could discriminate the grating, and proceeded to the next grating session. If the movement was ambiguous, the same grating session was presented again. All behavioral tests were double-blinded and performed during the first few hours of the animals’ light cycle (light on at 8 AM).
4. Results
4.1. Recording of VEP measurements in RCS rats
VEP measurements in 6- or 10-month-old RCS rats are expected to be abolished due to loss of photoreceptor cells. Generally, in RCS rats, photoreceptor degeneration is almost complete by 3 months after birth. Indeed, VEP measurements were not evoked even by the maximal LED flash in any of the aged RCS (rdy/rdy) rats (Fig. 2A). On the other hand, robust VEPs were evoked by the blue LED flash in RCS rats injected with the AAV-ChR2V vector (Fig. 2A). Initially, small VEP responses were observed at 2 weeks after AAV injection (data not shown), and the maximum amplitudes of VEP were observed 8 weeks later [58]. There were notable differences in sample waveforms from 6- and 10-month-old rats injected with AAV-ChR2V. Amplitudes and latencies of VEPs from 6-month-old rats were larger and shorter, respectively, than those from 10-month-old rats (Fig. 2B).
4.2. Transduction efficiencies of ChR2 in retinas of RCS rats
The expression of the ChR2 gene was evaluated by measuring Venus fluorescence in RCS rat retinas (Fig. 3A). The number of positive cells in rats injected at 10 months of age was significantly less than that injected at 6 months of age (Fig. 3B). The number of RGCs decreased linearly with age, following photoreceptor degeneration in the RCS rats (Fig. 3C). We have previously shown [56] that the ChR2 gene is mainly expressed in RGCs upon intravitreous injection of the AAV-ChR2V vector. Therefore, the observed decrease in the number of RGCs with age suggests that the transduction efficiencies at both ages are very similar.
4.3. Photoreceptor degeneration in Thy-I TG rats
There were 11–12 rows of photoreceptor nuclei in the outer nuclear layer (ONL) of the Thy-1 TG rats; this is a number usually observed in rodents without retinal degeneration [59]. Following continuous light exposure, photoreceptor cells disappeared (Fig. 4A). ERGs showed no response, indicating that the photoreceptor cells degenerated in the whole retina (Fig. 4B). However, robust VEP measurements could be recorded, even though the photoreceptor cells had completely degenerated (Fig. 4B). Intense expression of the ChR2 gene was observed in the entire retina, with about 45% of RGCs positive for ChR2 (Fig. 4C).
4.4. Behavioral assessment in photoreceptor degenerated-Thy-I TG rat
In our virtual optomotor system, a stimulus of blue stripes over a black background was produced according to a sine wave function with variable amplitude and frequency (Fig. 5A). All the photoreceptor-degenerated Thy-I TG and wild-type (normal) rats tracked the virtual rotating blue/black gratings (Fig. 5B). However, tracking stopped when the contrast was reduced below a specific threshold. We observed that contrast sensitivity was small at the minimal spatial frequency of 0.06 cycles per degree (CPD), increased with an increase in spatial frequency, and was negligible at spatial frequencies over 0.52 CPD. Therefore, the relationship followed an inverted U-shaped curve, as noted in previous reports [57]. In photoreceptor-degenerated Thy-I TG rats, no reduction of contrast sensitivity was observed at any spatial frequency. Unexpectedly, the contrast sensitivity was instead somewhat enhanced at low spatial frequencies such as 0.09 or 0.18 CPD (Fig. 5C).
5. Discussion
The photo-acquisition system of mammalian photoreceptor cells, which mediates various photoreceptor-specific proteins, is very complicated. In contrast, the corresponding system in green algae such as
Although VEP responses recovered after ChR2 gene transfer, the amplitudes and waveforms were different between rats injected with AAV-ChR2V at 6 and 10 months of age. One possibility is that RGC activity decayed after photoreceptor degeneration. However, our data show that the number of RGCs decreased after photoreceptor degeneration (Fig. 3C). The calculated RGC transduction efficiencies in 6-month-old rats were the same as those in 10-month-old rats. The differences in the recorded amplitudes and latencies shown in Fig. 2 appear to be due to differences in the number of photosensitive RGCs. We previously reported that the RGC transduction efficiency in 10-month-old rats was about 28% [38]. Subsequently, Isago et al. showed that the RGC transduction efficiencies in 6- and 10-month-old rats were 28.3 and 27.7%, respectively [56]. The data clearly indicates that the transduction efficiency is the same, although the number of ChR2-expressing cells was lower, corresponding to the decrease in the number of RGCs.
To investigate visual acuity resulting from ChR2-expressing RGCs, we established a TG rat model expressing the ChR2 gene in RGCs. Photoreceptor-degenerated TG rats clearly tracked the rotation of blue-black stripes in a virtual optomotor. However, RCS rats that received the ChR2 gene in the AAV vector did not track the rotation of the virtual optomotor at any spatial frequency. Recently, we tested the behavior of RCS rats using a mechanical optomotor system and showed that the intensity of luminosity the rat received was the most important factor influencing their tracking of the rotation of the column [53]. A luminosity of over 500 lux was needed to induce head tracking in ChR2-expressing RCS rats. However, the maximum luminosity of the virtual optomotor was about 100 lux. It was therefore too low to induce head tracking in RCS rats. The question then arises: what is the difference between the TG and RCS rats? We do not have a reasonable explanation for this. One possibility is that the number of ChR2-expressing RGCs in the TG rat is greater than that in the RCS rat. About 45% of the RGCs expressed ChR2 in the TG rat. Compared to the TG rat, the transduction efficiency in the RCS rat is about 28% independent of the age of the animal. This may affect the light sensitivity. As the another explanation, in the case of TG rats, ChR2 is expressed after birth; therefore, there is a possibility that retinal organization and function might be altered, that cannot be ruled out.
RGCs are merely one of the candidate cell types that could receive the ChR2 gene. Lagali et al. [60] succeeded in transferring the ChR2 gene into ON-bipolar cells in the retina and confirmed the restoration of visual and behavioral responses. ON- and OFF-bipolar cells receive synaptic input from photoreceptors. Considering that ChR2 can elicit light-on responses, ON-bipolar cells seem to be the most appropriate cells for the transfer of the ChR2 gene. However, 2 questions arise in this regard. First, how can we deliver the ChR2 gene into ON-bipolar cells for human gene therapy? Lagali et al. [60] transferred the ChR2 gene into neonatal mice by electroporation of the plasmid vector. It is generally difficult to transfer a gene into the depths of the retina via intravitreous injection of AAV vectors, in spite of the development of various serotypes of AAV vectors for retinal gene therapy [61-65]. Second, does synaptic transmission remain intact after photoreceptor degeneration? Some studies have reported that retinal remodeling is triggered in bipolar cells and horizontal cells following photoreceptor degeneration [66-70]. Recently, Doroudchi et al. [71] succeeded in transferring the ChR2 gene into ON-bipolar cells by the subretinal injection of a modified AAV vector (AAV8-Y733F) [72] that included a specific promoter for ON-bipolar cells (mGRM6-SV40), and demonstrated the behavioral recovery of the light response. These 2 questions could be resolved by these attractive methods used the specific promoter and the modified AAV vectors if the recovered visual acuity is investigated using a behavioral approach.
Since the discovery of ChR2, bacteriorhodopsins that have similar functions as that of ChR2 derived from
6. Conclusion
Target diseases for gene therapy were previously restricted to lethal and severe diseases that lead to death. In our country (Japan), the gene therapy guidelines were updated in 2002, whereby diseases in which bodily functions are severely impaired, such as loss of arms or legs, blindness, and deafness, were added to the list of target diseases for gene therapy. Based on these guidelines, people suffering from impaired vision caused by RP are eligible for gene therapy. However, gene therapy using genes derived from living organisms other than humans has not previously been tested in clinical trials. Safety studies, especially immunological reactions, using appropriate animal models in ChR2-based gene therapy is important before proceeding to clinical trials.
Acknowledgments
This work was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 24390393 and 23659804) and the Program for the Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO). We express our heartfelt appreciation to Dr. Ichiro Hagimori in Narita Animal Science Laboratory Co. Ltd., whose enormous support and insightful comments were invaluable during the course of this study.
References
- 1.
Jr., Barron Y, Moskowitz M, Klock IB, Milam AH. Morphometric analysis of the extramacular retina from postmortem eyes with retinitis pigmentosa. Invest Ophthalmol Vis SciHumayun M. S Prince M De Juan E 1999 40 1 143 148 - 2.
Jr., Greenburg RJ, Marsh MJ, Klock IB, Milam AH. Preservation of the inner retina in retinitis pigmentosa. A morphometric analysis. Arch OphthalmolSantos A Humayun M. S De Juan E 1997 115 4 511 515 - 3.
Jr., Milam AH. Morphometric analysis of macular photoreceptors and ganglion cells in retinas with retinitis pigmentosa. Arch OphthalmolStone J. L Barlow W. E Humayun M. S De Juan E 1992 110 11 1634 1639 - 4.
Retinitis pigmentosa. LancetHartong D. T Berson E. L Dryja T. P 2006 368 9549 1795 1809 - 5.
A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. NatureDryja T. P Mcgee T. L Reichel E Hahn L. B Cowley G. S Yandell D. W Sandberg M. A Berson E. L 1990 343 6256 364 366 - 6.
Leber congenital amaurosis- a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J OphthalmolStone E. M 2007 144 6 791 811 - 7.
Theodor Leber: a founder of ophthalmic research. Surv OphthalmolBlum M Hykin P. G Sanders M Volcker H. E 1992 37 1 63 68 - 8.
The phenotype of Leber congenital amaurosis in patients with AIPL1 mutations. Arch OphthalmolDharmaraj S Leroy B. P Sohocki M. M Koenekoop R. K Perrault I Anwar K Khaliq S Devi R. S Birch D. G De Pool E Izquierdo N Van Maldergem L Ismail M Payne A. M Holder G. E Bhattacharya S. S Bird A. C Kaplan J Maumenee I. H 2004 122 7 1029 1037 - 9.
Null RPGRIP1 alleles in patients with Leber congenital amaurosis. Am J Hum GenetDryja T. P Adams S. M Grimsby J. L Mcgee T. L Hong D. H Li T Andreasson S Berson E. L 2001 68 5 1295 1298 - 10.
Mutations in the CRB1 gene cause Leber congenital amaurosis. Arch OphthalmolLotery A. J Jacobson S. G Fishman G. A Weleber R. G Fulton A. B Namperumalsamy P Heon E Levin A. V Grover S Rosenow J. R Kopp K. K Sheffield V. C Stone E. M 2001 119 3 415 420 - 11.
Mutations in RPE65 cause Leber’s congenital amaurosis. Nat GenetMarlhens F Bareil C Griffoin J. M Zrenner E Amalric P Eliaou C Liu S. Y Harris E Redmond T. M Arnaud B Claustres M Hamel C. P 1997 17 2 139 141 - 12.
Le Paslier D, Frezal J, Dufier JL, Pittler S, Munnich A, Kaplan J. Retinal-specific guanylate cyclase gene mutations in Leber’s congenital amaurosis. Nat GenetPerrault I Rozet J. M Calvas P Gerber S Camuzat A Dollfus H Chatelin S Souied E Ghazi I Leowski C Bonnemaison M 1996 14 4 461 464 - 13.
Le Meur G, Hamel C, Silva E, Nitschke P, Calvas P, Munnich A, Roche O, Dollfus H, Kaplan J, Rozet JM. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat GenetPerrault I Hanein S Zanlonghi X Serre V Nicouleau M Defoort-delhemmes S Delphin N Fares-taie L Gerber S Xerri O Edelson C Goldenberg A Duncombe A 2012 in press. - 14.
van den Hurk JA, den Hollander AI. Molecular genetics of Leber congenital amaurosis. Hum Mol GenetCremers F. P 2002 11 10 1169 1176 - 15.
Gene therapy restores vision in a canine model of childhood blindness. Nat GenetAcland G. M Aguirre G. D Ray J Zhang Q Aleman T. S Cideciyan A. V Pearce-kelling S. E Anand V Zeng Y Maguire A. M Jacobson S. G Hauswirth W. W Bennett J 2001 28 1 92 95 - 16.
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol TherAcland G. M Aguirre G. D Bennett J Aleman T. S Cideciyan A. V Bennicelli J Dejneka N. S Pearce-kelling S. E Maguire A. M Palczewski K Hauswirth W. W Jacobson S. G 2005 12 6 1072 1082 - 17.
Clinical and molecular genetics of Leber’s congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis SciSimonelli F Ziviello C Testa F Rossi S Fazzi E Bianchi P. E Fossarello M Signorini S Bertone C Galantuomo S Brancati F Valente E. M Ciccodicola A Rinaldi E Auricchio A Banfi S 2007 48 9 4284 4290 - 18.
Vision 1 year after gene therapy for Leber’s congenital amaurosis. N Engl J MedCideciyan A. V Hauswirth W. W Aleman T. S Kaushal S Schwartz S. B Boye S. L Windsor E. A Conlon T. J Sumaroka A Roman A. J Byrne B. J Jacobson S. G 2009 361 7 725 727 - 19.
Jr., Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell’Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J MedMaguire A. M Simonelli F Pierce E. A Pugh E. N 2008 358 21 2240 2248 - 20.
Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J MedBainbridge J. W Smith A. J Barker S. S Robbie S Henderson R Balaggan K Viswanathan A Holder G. E Stockman A Tyler N Petersen-jones S Bhattacharya S. S Thrasher A. J Fitzke F. W Carter B. J Rubin G. S Moore A. T Ali R. R 2008 358 21 2231 2239 - 21.
Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. LancetMaguire A. M High K. A Auricchio A Wright J. F Pierce E. A Testa F Mingozzi F Bennicelli J. L Ying G. S Rossi S Fulton A Marshall K. A Banfi S Chung D. C Morgan J. I Hauck B Zelenaia O Zhu X Raffini L Coppieters F De Baere E Shindler K. S Volpe N. J Surace E. M Acerra C Lyubarsky A Redmond T. M Stone E Sun J Mcdonnell J. W Leroy B. P Simonelli F Bennett J 2009 374 9701 1597 1605 - 22.
Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol TherSimonelli F Maguire A. M Testa F Pierce E. A Mingozzi F Bennicelli J. L Rossi S Marshall K Banfi S Surace E. M Sun J Redmond T. M Zhu X Shindler K. S Ying G. S Ziviello C Acerra C Wright J. F Mcdonnell J. W High K. A Bennett J Auricchio A 2010 18 3 643 650 - 23.
Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients. Hum Gene TherColella P Auricchio A 2012 23 8 796 807 - 24.
Autosomal dominant retinitis pigmentosa with rhodopsin, valine-345-methionine. Trans Am Ophthalmol SocBerson E. L Sandberg M. A Dryja T. P 1991 89 117 128 discussion 128-130. - 25.
Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. NeuronOlsson J. E Gordon J. W Pawlyk B. S Roof D Hayes A Molday R. S Mukai S Cowley G. S Berson E. L Dryja T. P 1992 9 5 815 830 - 26.
Apoptosis: final common pathway of photoreceptor death in rd, rds, and rhodopsin mutant mice. NeuronChang G. Q Hao Y Wong F 1993 11 4 595 605 - 27.
LaVail MM, Kotake Y, Anderson RE. Free radical trap phenyl-N-tert-butylnitrone protects against light damage but does not rescueRanchon I 23H and S334ter rhodopsin transgenic rats from inherited retinal degeneration. J Neurosci2003 - 28.
Mechanism of protection from light-induced retinal degeneration by the synthetic antioxidant phenyl-N-tert-butylnitrone. Invest Ophthalmol Vis SciTomita H Kotake Y Anderson R. E 2005 46 2 427 434 - 29.
Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum Gene TherCayouette M Gravel C 1997 8 4 423 430 - 30.
Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene TherJomary C Vincent K. A Grist J Neal M. J Jones S. E 1997 4 7 683 690 - 31.
Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse. Gene TherBennett J Zeng Y Bajwa R Klatt L Li Y Maguire A. M 1998 5 9 1156 1164 - 32.
The subretinal microphotodiode array retinal prosthesis II. Ophthalmic ResChow A. Y Peachey N 1999 - 33.
Artificial vision for the blind by connecting a television camera to the visual cortex. ASAIO JDobelle W. H 2000 46 1 3 9 - 34.
rd, Wyatt J, Loewenstein J, Kelly S, Shire D. Perceptual efficacy of electrical stimulation of human retina with a microelectrode array during short-term surgical trials. Invest Ophthalmol Vis SciRizzo J. F 2003 44 12 5362 5369 - 35.
Subretinal electrical stimulation of the rabbit retina with acutely implanted electrode arrays. Graefes Arch Clin Exp OphthalmolGekeler F Kobuch K Schwahn H. N Stett A Shinoda K Zrenner E 2004 242 7 587 596 - 36.
Retinal prostheses: current clinical results and future needs. OphthalmologyWeiland J. D Cho A. K Humayun M. S 2011 118 11 2227 2237 - 37.
Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. NeuronBi A Cui J Ma Y. P Olshevskaya E Pu M Dizhoor A. M Pan Z. H 2006 50 1 23 33 - 38.
Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. Invest Ophthalmol Vis SciTomita H Sugano E Yawo H Ishizuka T Isago H Narikawa S Kugler S Tamai M 2007 48 8 3821 3826 - 39.
Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci U S ANagel G Szellas T Huhn W Kateriya S Adeishvili N Berthold P Ollig D Hegemann P Bamberg E 2003 100 24 13940 13945 - 40.
Millisecond-timescale, genetically targeted optical control of neural activity. Nat NeurosciBoyden E. S Zhang F Bamberg E Nagel G Deisseroth K 2005 8 9 1263 1268 - 41.
Kinetic evaluation of photosensitivity in genetically engineered neurons expressing green algae light-gated channels. Neurosci ResIshizuka T Kakuda M Araki R Yawo H 2006 54 2 85 94 - 42.
Fast noninvasive activation and inhibition of neural and network activity by vertebrate rhodopsin and green algae channelrhodopsin. Proc Natl Acad Sci U S ALi X Gutierrez D. V Hanson M. G Han J Mark M. D Chiel H Hegemann P Landmesser L. T Herlitze S 2005 102 49 17816 17821 - 43.
LaVail MM, Sidman RL, O’Neil D. Photoreceptor-pigment epithelial cell relationships in rats with inherited retinal degeneration. Radioautographic and electron microscope evidence for a dual source of extra lamellar material. J Cell Biol1972 53 1 185 209 - 44.
LaVail MM. Inherited retinal dystrophy: primary defect in pigment epithelium determined with experimental rat chimeras. ScienceMullen R. J 1976 192 4241 799 801 - 45.
, Vollrath D. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet 2000;9(4):645-651.D ’Cruz PM ,Yasumura D ,Weir J ,Matthes MT ,Abderrahim Vail MMH ,La - 46.
Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat GenetGal A Li Y Thompson D. A Weir J Orth U Jacobson S. G Apfelstedt-sylla E Vollrath D 2000 26 3 270 271 - 47.
Visual properties of transgenic rats harboring the channelrhodopsin-2 gene regulated by the thy-1.2 promoter. PLoS OneTomita H Sugano E Fukazawa Y Isago H Sugiyama Y Hiroi T Ishizuka T Mushiake H Kato M Hirabayashi M Shigemoto R Yawo H Tamai M 2009 e7679. - 48.
Localizatin of the Thy-1 antigen in rat brain and spinal cord by immunofluorescence. J NeurochemBarclay A. N Hyden H 1978 31 6 1375 1391 - 49.
The kinetics of antibody binding to membrane antigens in solution and at the cell surface. Biochem JMason D. W Williams A. F 1980 187 1 1 20 - 50.
Thy-1 antigen: a ganglion cell specific marker in rodent retina. NeuroscienceBarnstable C. J Drager U. C 1984 11 4 847 855 - 51.
Is Thy-1 expressed only by ganglion cells and their axons in the retina and optic nerve? J NeurocytolPerry V. H Morris R. J Raisman G 1984 13 5 809 824 - 52.
Establishment of effective methods for transducing genes into iris pigment epithelial cells by using adeno-associated virus type 2. Invest Ophthalmol Vis SciSugano E Tomita H Ishiguro S Abe T Tamai M 2005 46 9 3341 3348 - 53.
Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats. Exp Eye ResTomita H Sugano E Isago H Hiroi T Wang Z Ohta E Tamai M 2010 90 3 429 436 - 54.
The effects of certain H(1)-antagonists on visual evoked potential in rats. Brain Res BullIwamura Y Fujii Y Kamei C 2003 61 4 393 398 - 55.
Visual cortical plasticity following unilateral sensorimotor cortical lesions in the neonatal rat. Exp NeurolPapathanasiou E. S Peachey N. S Goto Y Neafsey E. J Castro A. J Kartje G. L 2006 199 1 122 129 - 56.
Age-dependent differences in recovered visual responses in Royal College of Surgeons rats transduced with the Channelrhodopsin-2 gene. J Mol NeurosciIsago H Sugano E Wang Z Murayama N Koyanagi E Tamai M Tomita H 2012 46 2 393 400 - 57.
Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis SciPrusky G. T Alam N. M Beekman S Douglas R. M 2004 45 12 4611 4616 - 58.
Immune responses to adeno-associated virus type 2 encoding channelrhodopsin-2 in a genetically blind rat model for gene therapy. Gene TherSugano E Isago H Wang Z Murayama N Tamai M Tomita H 2011 18 3 266 274 - 59.
Morphologic comparisons between rhodopsin-mediated and short-wavelength classes of retinal light damage. Invest Ophthalmol Vis SciRapp L. M Smith S. C 1992 33 12 3367 3377 - 60.
Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat NeurosciLagali P. S Balya D Awatramani G. B Munch T. A Kim D. S Busskamp V Cepko C. L Roska B 2008 11 6 667 675 - 61.
J. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol GenetAuricchio A Kobinger G Anand V Hildinger M O Connor E Maguire A. M Wilson J. M Bennett 2001 10 26 3075 3081 - 62.
Differential lineage restriction of rat retinal progenitor cells in vitro and in vivo. J Neurosci ResYang P Seiler M. J Aramant R. B Whittemore S. R 2002 69 4 466 476 - 63.
Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol TherWeber M Rabinowitz J Provost N Conrath H Folliot S Briot D Cherel Y Chenuaud P Samulski J Moullier P Rolling F 2003 7 6 774 781 - 64.
Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum Gene TherLotery A. J Derksen T. A Russell S. R Mullins R. F Sauter S Affatigato L. M Stone E. M Davidson B. L 2002 13 6 689 696 - 65.
Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J VirolAllocca M Mussolino C Garcia-hoyos M Sanges D Iodice C Petrillo M Vandenberghe L. H Wilson J. M Marigo V Surace E. M Auricchio A 2007 81 20 11372 11380 - 66.
Neural reprogramming in retinal degeneration. Invest Ophthalmol Vis SciMarc R. E Jones B. W Anderson J. R Kinard K Marshak D. W Wilson J. H Wensel T Lucas R. J 2007 48 7 3364 3371 - 67.
Neural remodeling in retinal degeneration. Prog Retin Eye ResMarc R. E Jones B. W Watt C. B Strettoi E 2003 22 5 607 655 - 68.
Modifications of retinal neurons in a mouse model of retinitis pigmentosa. Proc Natl Acad Sci U S AStrettoi E Pignatelli V 2000 97 20 11020 11025 - 69.
Remodeling of second-order neurons in the retina of rd/rd mutant mice. Vision ResStrettoi E Pignatelli V Rossi C Porciatti V Falsini B 2003 43 8 867 877 - 70.
Morphological and functional abnormalities in the inner retina of the rd/rd mouse. J NeurosciStrettoi E Porciatti V Falsini B Pignatelli V Rossi C 2002 22 13 5492 5504 - 71.
Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol TherDoroudchi M. M Greenberg K. P Liu J Silka K. A Boyden E. S Lockridge J. A Arman A. C Janani R Boye S. E Boye S. L Gordon G. M Matteo B. C Sampath A. P Hauswirth W. W Horsager A 2011 19 7 1220 1229 - 72.
Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol TherPang J. J Dai X Boye S. E Barone I Boye S. L Mao S Everhart D Dinculescu A Liu L Umino Y Lei B Chang B Barlow R Strettoi E Hauswirth W. W 2011 19 2 234 242 - 73.
Red-shifted optogenetic excitation: a tool for fast neural control derived from Volvox carteri. Nat NeurosciZhang F Prigge M Beyriere F Tsunoda S. P Mattis J Yizhar O Hegemann P Deisseroth K 2008 11 6 631 633 - 74.
Ectopic expression of multiple microbial rhodopsins restores ON and OFF light responses in retinas with photoreceptor degeneration. J NeurosciZhang Y Ivanova E Bi A Pan Z. H 2009 29 29 9186 9196 - 75.
Structure of the light-driven chloride pump halorhodopsin at 1.8 A resolution. ScienceKolbe M Besir H Essen L. O Oesterhelt D 2000 288 5470 1390 1396 - 76.
New channelrhodopsin with a red-shifted spectrum and rapid kinetics from Mesostigma viride. MBioGovorunova E. G Spudich E. N Lane C. E Sineshchekov O. A Spudich J. L 2011 e00115 e00111. - 77.
Color-tuned Channelrhodopsins for Multiwavelength Optogenetics. J Biol ChemPrigge M Schneider F Tsunoda S. P Shilyansky C Wietek J Deisseroth K Hegemann P 2012 in press. - 78.
Molecular determinants differentiating photocurrent properties of two channelrhodopsins from chlamydomonas. J Biol ChemWang H Sugiyama Y Hikima T Sugano E Tomita H Takahashi T Ishizuka T Yawo H 2009 284 9 5685 5696